Beigene (NASDAQ:ONC) Announces Quarterly Earnings Results

Posted by Carol Hyndes on Feb 28th, 2025

Beigene (NASDAQ:ONC – Get Free Report) posted its earnings results on Thursday. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55), Zacks reports. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1.13 billion during the quarter, compared to analysts’ expectations of $1.09 billion. Beigene updated its FY 2025 guidance to EPS.

Beigene Price Performance

NASDAQ ONC traded down $8.85 during mid-day trading on Friday, reaching $269.53. 488,249 shares of the company’s stock traded hands, compared to its average volume of 408,622. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. Beigene has a 1-year low of $126.97 and a 1-year high of $287.88. The firm has a market cap of $26.38 billion, a PE ratio of -32.71, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Separately, Macquarie boosted their price target on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday.

Get Our Latest Research Report on ONC

Insider Activity

In other news, COO Xiaobin Wu sold 30,654 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $258.04, for a total value of $310,164.08. The disclosure for this sale can be found here. In the last ninety days, insiders sold 58,123 shares of company stock worth $14,081,527. 7.43% of the stock is currently owned by insiders.

Beigene Company Profile

(Get Free Report)

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.